ISIS Pharmaceuticals (NASDAQ:ISIS) SVP C Frank Bennett sold 11,200 shares of the stock on the open market in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $36.78, for a total value of $411,936.00. Following the transaction, the senior vice president now directly owns 4,336 shares of the company’s stock, valued at approximately $159,478. The sale was disclosed in a document filed with the Securities & Exchange Commission. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) net profit margin is -69.60% and weekly performance is -13.00%. On last trading day company shares ended up $30.91. Analysts mean target price for the company is $43.56. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) distance from 50-day simple moving average is 3.17%.
Nuun is now sponsoring Team Novo Nordisk, a global all-diabetes team of cyclists, triathletes and runners, spearheaded by the world’s first all-diabetes professional cycling team. As the Official Hydration Sponsor, Nuun is providing hydration products for all team members in their training, racing and recovery.Novo Nordisk A/S (ADR) (NYSE:NVO) shares fell -0.11% in last trading session and ended the day on $45.40. NVO Gross Margin is 83.30% and its return on assets is 38.60%. Novo Nordisk A/S (ADR) (NYSE:NVO) quarterly performance is 4.13%.
On July 1,2014 Pershing Square, managed by Bill Ackman, revealed in a new filing with the U.S. Securities and Exchange Commission that it has settled a lawsuit with Allergan Inc. (NYSE:AGN). Pershing Square owns 28.88 million shares of Allergan Inc. (NYSE:AGN), the stake is equal to 9.7% of common stock.Allergan, Inc. (NYSE:AGN) shares moved down -0.52% in last trading session and was closed at $165.20, while trading in range of $164.45-$166.15. Allergan, Inc. (NYSE:AGN) year to date performance is 48.83%.
On May 19, 2014, Gerard Michel, the Chief Financial Officer of Biodel Inc. (NASDAQ;BIOD), provided notice of his intention to resign from the Company effective May 30, 2014 to pursue a new career opportunity. The Company is in the process of commencing an external search for its next Chief Financial Officer. Effective as of May 30, 2014, Errol De Souza, the Company’s President and Chief Executive Officer, will assume the role of principal financial officer until a replacement Chief Financial Officer is appointed. Biodel Inc (NASDAQ:BIOD) ended the last trading day at $2.02. Company weekly volatility is calculated as 4.02% and price to cash ratio as 1.49. Biodel Inc (NASDAQ:BIOD) showed a negative weekly performance of -5.61%.
Lannett Company (NYSE:LCI) major shareholder David Farber sold 7,500 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $50.00, for a total value of $375,000.00. Following the completion of the transaction, the insider now directly owns 70,000 shares in the company, valued at approximately $3,500,000. The sale was disclosed in a filing with the SEC. Lannett Company, Inc. (NYSE:LCI) net profit margin is 13.30% and weekly performance is -6.63%. On last trading day company shares ended up $46.65. Analysts mean target price for the company is $47.25. Lannett Company, Inc. (NYSE:LCI) distance from 50-day simple moving average is 10.05%.